APA (7th ed.) Citation

EJ, T., & T, R. (2020). FGF21: An Emerging Therapeutic Target for Non-Alcoholic Steatohepatitis and Related Metabolic Diseases. Frontiers in endocrinology, 11, 601290. https://doi.org/10.3389/fendo.2020.601290

Chicago Style (17th ed.) Citation

EJ, Tillman, and Rolph T. "FGF21: An Emerging Therapeutic Target for Non-Alcoholic Steatohepatitis and Related Metabolic Diseases." Frontiers in Endocrinology 11 (2020): 601290. https://doi.org/10.3389/fendo.2020.601290.

MLA (9th ed.) Citation

EJ, Tillman, and Rolph T. "FGF21: An Emerging Therapeutic Target for Non-Alcoholic Steatohepatitis and Related Metabolic Diseases." Frontiers in Endocrinology, vol. 11, 2020, p. 601290, https://doi.org/10.3389/fendo.2020.601290.